Literature DB >> 20924013

Evaluating the risks of clinical research.

Annette Rid1, Ezekiel J Emanuel, David Wendler.   

Abstract

The ethical appropriateness of clinical research depends on protecting participants from excessive risks. Yet no systematic framework has been developed to assess research risks, and as a result, investigators, funders, and review boards rely only on their intuitive judgments. Because intuitive judgments of risk are subject to well-documented cognitive biases, this approach raises concern that research participants are not being adequately protected. To address this situation, we delineate a method called the systematic evaluation of research risks (SERR), which evaluates the risks of research interventions by comparing these interventions with the risks of comparator activities that have been deemed acceptable. This method involves a 4-step process: (1) identify the potential harms posed by the proposed research intervention; (2) categorize the magnitude of the potential harms into 1 of 7 harm levels on a harm scale; (3) quantify or estimate the likelihood of each potential harm; and (4) compare the likelihood of each potential harm from the research intervention with the likelihood of harms of the same magnitude occurring as a result of an appropriate comparator activity. By explicitly delineating, quantifying, and comparing the risks of research interventions with the risks posed by appropriate comparator activities, SERR offers a way to minimize the influence of cognitive biases on the evaluation of research risks and thereby better protect research participants from excessive risks.

Entities:  

Mesh:

Year:  2010        PMID: 20924013     DOI: 10.1001/jama.2010.1414

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

2.  Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects.

Authors:  David L Evers; Carol B Fowler; Jeffrey T Mason; Rebecca K Mimnall
Journal:  Sci Eng Ethics       Date:  2014-08-24       Impact factor: 3.525

3.  Rethinking risk assessment for emerging technology first-in-human trials.

Authors:  Anna Genske; Sabrina Engel-Glatter
Journal:  Med Health Care Philos       Date:  2016-03

4.  Uncertainty and equipoise: at interplay between epistemology, decision making and ethics.

Authors:  Benjamin Djulbegovic
Journal:  Am J Med Sci       Date:  2011-10       Impact factor: 2.378

5.  Minimal Risk in Pediatric Research: A Philosophical Review and Reconsideration.

Authors:  John Rossi; Robert M Nelson
Journal:  Account Res       Date:  2017-08-04       Impact factor: 2.622

6.  Risk, Russian-roulette and lotteries: Persson and Savulescu on moral enhancement.

Authors:  Darryl Gunson; Hugh McLachlan
Journal:  Med Health Care Philos       Date:  2013-11

7.  Evaluating the risks of clinical research: direct comparative analysis.

Authors:  Annette Rid; Emily Abdoler; Roxann Roberson-Nay; Daniel S Pine; David Wendler
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-09       Impact factor: 2.576

8.  Do U.S. regulations allow more than minor increase over minimal risk pediatric research? Should they?

Authors:  David Wendler
Journal:  IRB       Date:  2013 Nov-Dec

9.  Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events.

Authors:  Lisa McManus; Arlene Davis; Rebecca L Forcier; Jill A Fisher
Journal:  J Law Med Ethics       Date:  2019-06       Impact factor: 1.718

10.  Setting risk thresholds in biomedical research: lessons from the debate about minimal risk.

Authors:  Annette Rid
Journal:  Monash Bioeth Rev       Date:  2014 Mar-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.